Upregulation of the EGFR/MEK1/MAPK1/2 signaling axis as a mechanism of resistance to antiestrogen‑induced BimEL dependent apoptosis in ER<sup>+</sup> breast cancer cells

Hagan,Mackenzie L.; Mander,Suchreet; Joseph,Carol; McGrath,Michael; Barrett,Amanda; Lewis,Allison; Hill,William D.; Browning,Darren; McGee‑Lawrence,Meghan E.; Cai,Haifeng; Liu,Kebin; Barrett,John T.; Gewirtz,David A.; Thangaraju,Muthusamy; Schoenlein,Patricia V.

doi:10.3892/ijo.2022.5468

Upregulation of the EGFR/MEK1/MAPK1/2 signaling axis as a mechanism of resistance to antiestrogen‑induced BimEL dependent apoptosis in ER⁺ breast cancer cells

Authors:
- Mackenzie L. Hagan
- Suchreet Mander
- Carol Joseph
- Michael McGrath
- Amanda Barrett
- Allison Lewis
- William D. Hill
- Darren Browning
- Meghan E. McGee‑Lawrence
- Haifeng Cai
- Kebin Liu
- John T. Barrett
- David A. Gewirtz
- Muthusamy Thangaraju
- Patricia V. Schoenlein
View Affiliations

Affiliations: Department of Cellular Biology and Anatomy, Augusta University, Augusta, GA 30912, USA, Department of Pathology, Augusta University, Augusta, GA 30912, USA, Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425, USA, Medical College of Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA, Department of Pharmacology and Toxicology, Massey Cancer Center, Richmond, VA 23298, USA
Published online on: December 16, 2022 https://doi.org/10.3892/ijo.2022.5468
Article Number: 20
Copyright: © Hagan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The epidermal growth factor receptor (EGFR) is commonly upregulated in multiple cancer types, including breast cancer. In the present study, evidence is provided in support of the premise that upregulation of the EGFR/MEK1/MAPK1/2 signaling axis during antiestrogen treatment facilitates the escape of breast cancer cells from BimEL‑dependent apoptosis, conferring resistance to therapy. This conclusion is based on the findings that ectopic BimEL cDNA overexpression and confocal imaging studies confirm the pro‑apoptotic role of BimEL in ERα expressing breast cancer cells and that upregulated EGFR/MEK1/MAPK1/2 signaling blocks BimEL pro‑apoptotic action in an antiestrogen‑resistant breast cancer cell model. In addition, the present study identified a pro‑survival role for autophagy in antiestrogen resistance while EGFR inhibitor studies demonstrated that a significant percentage of antiestrogen‑resistant breast cancer cells survive EGFR targeting by pro‑survival autophagy. These pre‑clinical studies establish the possibility that targeting both the MEK1/MAPK1/2 signaling axis and pro‑survival autophagy may be required to eradicate breast cancer cell survival and prevent the development of antiestrogen resistance following hormone treatments. The present study uniquely identified EGFR upregulation as one of the mechanisms breast cancer cells utilize to evade the cytotoxic effects of antiestrogens mediated through BimEL‑dependent apoptosis.

View Figures

View References

1	Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E and Zackrisson S: Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26(Suppl 5): v8–v30. 2015. View Article : Google Scholar : PubMed/NCBI
2	Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
3	Strasser-Weippl K, Badovinac-Crnjevic T, Fan L and Goss PE: Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer. Breast. 22(Suppl 2): S171–S175. 2013. View Article : Google Scholar : PubMed/NCBI
4	Nardone A, De Angelis C, Trivedi MV, Osborne CK and Schiff R: The changing role of ER in endocrine resistance. Breast. 24(Suppl 2): S60–S66. 2015. View Article : Google Scholar : PubMed/NCBI
5	Dodwell D, Wardley A and Johnston S: Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors. Breast. 15:584–594. 2006. View Article : Google Scholar : PubMed/NCBI
6	Hartkopf AD, Grischke EM and Brucker SY: Endocrine-resistant breast cancer: Mechanisms and treatment. Breast Care (Basel). 15:347–354. 2020. View Article : Google Scholar : PubMed/NCBI
7	Clarke R, Jones BC, Sevigny CM, Hilakivi-Clarke LA and Sengupta S: Experimental models of endocrine responsive breast cancer: Strengths, limitations, and use. Cancer Drug Resist. 4:762–783. 2021.PubMed/NCBI
8	Shah M, Nunes MR and Stearns V: CDK4/6 inhibitors: Game changers in the management of hormone receptor-positive advanced breast cancer? Oncology (Williston Park). 32:216–222. 2018.PubMed/NCBI
9	Li Z, Zou W, Zhang J, Zhang Y, Xu Q, Li S and Chen C: Mechanisms of CDK4/6 inhibitor resistance in luminal breast cancer. Front Pharmacol. 11:5802512020. View Article : Google Scholar : PubMed/NCBI
10	Sharifi MN, Anandan A, Grogan P and O'Regan RM: Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies. Cancer. 126:3400–3416. 2020. View Article : Google Scholar : PubMed/NCBI
11	Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG and Schoenlein PV: Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res. 10:5215–5225. 2004. View Article : Google Scholar : PubMed/NCBI
12	Schoenlein PV, Hou M, Samaddar JS, Gaddy VT, Thangaraju M, Lewis J, Johnson M, Ganapathy V, Kallab A and Barrett JT: Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer. Int J Oncol. 31:643–655. 2007.PubMed/NCBI
13	El Etreby MF, Liang Y, Wrenn RW and Schoenlein PV: Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 51:149–168. 1998. View Article : Google Scholar
14	El Etreby MF and Liang Y: Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat. 49:109–117. 1998. View Article : Google Scholar : PubMed/NCBI
15	Klijn JG, Setyono-Han B and Foekens JA: Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 65:825–830. 2000. View Article : Google Scholar : PubMed/NCBI
16	Periyasamy-Thandavan S, Takhar S, Singer A, Dohn MR, Jackson WH, Welborn AE, LeRoith D, Marrero M, Thangaraju M, Huang S and Schoenlein PV: Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim. Breast Cancer Res. 14:R522012. View Article : Google Scholar : PubMed/NCBI
17	Ying HQ, Chen J, He BS, Pan YQ, Wang F, Deng QW, Sun HL, Liu X and Wang SK: The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy. Sci Rep. 5:113482015. View Article : Google Scholar : PubMed/NCBI
18	Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet JP, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, et al: MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: Rationale to combine romidepsin with an MEK inhibitor. Blood. 121:4115–4125. 2013. View Article : Google Scholar : PubMed/NCBI
19	Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH and Murphy LC: Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res. 8:1747–1753. 2002.PubMed/NCBI
20	Lin CH, Shen CY, Lee JH, Huang CS, Yang CH, Kuo WH, Chang DY, Hsiung CN, Kuo KT, Chen WW, et al: High prevalence of the BIM deletion polymorphism in young female breast cancer in an East Asian country. PLoS One. 10:e01249082015. View Article : Google Scholar : PubMed/NCBI
21	Sionov RV, Vlahopoulos SA and Granot Z: Regulation of Bim in health and disease. Oncotarget. 6:23058–23134. 2015. View Article : Google Scholar : PubMed/NCBI
22	Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ, Browning D, Rawson J, Smith SB, Barrett JT and Schoenlein PV: A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther. 7:2977–2987. 2008. View Article : Google Scholar : PubMed/NCBI
23	Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR, Raney L, Gopal E, Ganapathy V, Hill WD, Bhalla KN and Schoenlein PV: Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy. 6:19–35. 2010. View Article : Google Scholar : PubMed/NCBI
24	Towers CG, Wodetzki D and Thorburn A: Autophagy and cancer: Modulation of cell death pathways and cancer cell adaptations. J Cell Biol. 219:e2019090332020.
25	Marchetti S, Gimond C, Chambard JC, Touboul T, Roux D, Pouysségur J and Pagès G: Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation. Mol Cell Biol. 25:854–864. 2005. View Article : Google Scholar : PubMed/NCBI
26	Jeong JE, Park JH, Kim CS, Lee SL, Chung HL, Kim WT and Lee EJ: Neuroprotective effects of erythropoietin against hypoxic injury via modulation of the mitogen-activated protein kinase pathway and apoptosis. Korean J Pediatr. 60:181–188. 2017. View Article : Google Scholar : PubMed/NCBI
27	Sander H, Wallace S, Plouse R, Tiwari S and Gomes AV: Ponceau S waste: Ponceau S staining for total protein normalization. Anal Biochem. 575:44–53. 2019. View Article : Google Scholar : PubMed/NCBI
28	Palumbo C, De Luca A, Rosato N, Forgione M, Rotili D and Caccuri AM: c-Jun N-terminal kinase activation by nitrobenzoxadiazoles leads to late-stage autophagy inhibition. J Transl Med. 14:372016. View Article : Google Scholar : PubMed/NCBI
29	Ewings KE, Wiggins CM and Cook SJ: Bim and the pro-survival Bcl-2 proteins: Opposites attract, ERK repels. Cell Cycle. 6:2236–2240. 2007. View Article : Google Scholar : PubMed/NCBI
30	Rani A, Stebbing J, Giamas G and Murphy J: Endocrine resistance in hormone receptor positive breast cancer-from mechanism to therapy. Front Endocrinol (Lausanne). 10:2452019. View Article : Google Scholar : PubMed/NCBI
31	Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A and Lien EA: Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res. 10:2336–2343. 2004. View Article : Google Scholar : PubMed/NCBI
32	Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al: Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 8:445–544. 2012. View Article : Google Scholar : PubMed/NCBI
33	Mizushima N, Yoshimori T and Levine B: Methods in mammalian autophagy research. Cell. 140:313–326. 2010. View Article : Google Scholar : PubMed/NCBI
34	Mizushima N and Yoshimori T: How to interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007. View Article : Google Scholar : PubMed/NCBI
35	Tang J, Li Y, Xia S, Li J, Yang Q, Ding K and Zhang H: Sequestosome 1/p62: A multitasker in the regulation of malignant tumor aggression (Review). Int J Oncol. 59:772021. View Article : Google Scholar : PubMed/NCBI
36	Shao S, Li S, Qin Y, Wang X, Yang Y, Bai H, Zhou L, Zhao C and Wang C: Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int J Oncol. 44:1661–1668. 2014. View Article : Google Scholar : PubMed/NCBI
37	Honda A, Harrington E, Cornella-Taracido I, Furet P, Knapp MS, Glick M, Triantafellow E, Dowdle WE, Wiedershain D, Maniara W, et al: Potent, selective, and orally bioavailable inhibitors of VPS34 provide chemical tools to modulate autophagy in vivo. ACS Med Chem Lett. 7:72–76. 2015. View Article : Google Scholar
38	Normanno N, Maiello MR and De Luca A: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action? J Cell Physiol. 194:13–19. 2003. View Article : Google Scholar
39	Thomas RS, Sarwar N, Phoenix F, Coombes RC and Ali S: Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. J Mol Endocrinol. 40:173–184. 2008. View Article : Google Scholar : PubMed/NCBI
40	Merino D, Best SA, Asselin-Labat ML, Vaillant F, Pal B, Dickins RA, Anderson RL, Strasser A, Bouillet P, Lindeman GJ and Visvader JE: Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2. Oncogene. 34:3926–3934. 2015. View Article : Google Scholar
41	Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, et al: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 22:4456–4462. 2004. View Article : Google Scholar : PubMed/NCBI
42	Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 26:2139–2146. 2008. View Article : Google Scholar : PubMed/NCBI
43	Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ II, de Cremoux P, Stenvang J and Lykkesfeldt AE: Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat. 114:263–275. 2009. View Article : Google Scholar :
44	Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK and Osborne CK: Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 10:331S–336S. 2004. View Article : Google Scholar : PubMed/NCBI
45	Gee JM, Robertson JF, Ellis IO and Nicholson RI: Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer. 95:247–254. 2001. View Article : Google Scholar : PubMed/NCBI
46	Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, Mueller A, Berset C, Wiliders H, Perey L, Rudolf CB, et al: Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer. 51:1212–1220. 2015. View Article : Google Scholar : PubMed/NCBI
47	Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN and Ueno NT: MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Mol Cancer Ther. 14:2773–2781. 2015. View Article : Google Scholar : PubMed/NCBI
48	Zattarin E, Leporati R, Ligorio F, Lobefaro R, Vingiani A, Pruneri G and Vernieri C: Hormone receptor loss in breast cancer: Molecular mechanisms, clinical settings, and therapeutic implications. Cells. 9:26442020. View Article : Google Scholar : PubMed/NCBI
49	Jeong Y, Bae SY, You D, Jung SP, Choi HJ, Kim I, Lee SK, Yu J, Kim SW, Lee JE, et al: EGFR is a therapeutic target in hormone receptor-positive breast cancer. Cell Physiol Biochem. 53:805–819. 2019. View Article : Google Scholar : PubMed/NCBI
50	Debacq-Chainiaux F, Erusalimsky JD, Campisi J and Toussaint O: Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc. 4:1798–1806. 2009. View Article : Google Scholar : PubMed/NCBI
51	Chen Y, Henson ES, Xiao W, Huang D, McMillan-Ward EM, Israels SJ and Gibson SB: Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia. Autophagy. 12:1029–1046. 2016. View Article : Google Scholar : PubMed/NCBI